PRTCL Stock Overview
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PureTech Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.70 |
| 52 Week High | UK£2.39 |
| 52 Week Low | UK£1.39 |
| Beta | 0.99 |
| 11 Month Change | 12.55% |
| 3 Month Change | 2.65% |
| 1 Year Change | 4.28% |
| 33 Year Change | -45.21% |
| 5 Year Change | -37.81% |
| Change since IPO | 26.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRTCL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.9% | 0.3% | 2.2% |
| 1Y | 4.3% | -18.3% | 8.0% |
Return vs Industry: PRTCL exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: PRTCL underperformed the UK Market which returned 8% over the past year.
Price Volatility
| PRTCL volatility | |
|---|---|
| PRTCL Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PRTCL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: PRTCL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 90 | Bharatt Chowrira | www.puretechhealth.com |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
PureTech Health plc Fundamentals Summary
| PRTCL fundamental statistics | |
|---|---|
| Market cap | UK£409.89m |
| Earnings (TTM) | -UK£65.81m |
| Revenue (TTM) | UK£373.49k |
1,097x
P/S Ratio-6.2x
P/E RatioIs PRTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTCL income statement (TTM) | |
|---|---|
| Revenue | US$468.00k |
| Cost of Revenue | US$82.02m |
| Gross Profit | -US$81.55m |
| Other Expenses | US$917.00k |
| Earnings | -US$82.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -17,425.00% |
| Net Profit Margin | -17,620.94% |
| Debt/Equity Ratio | 40.7% |
How did PRTCL perform over the long term?
See historical performance and comparison